Hopes rise for patients with drug resistant HIVBMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7355.62/a (Published 13 July 2002) Cite this as: BMJ 2002;325:62
- Alex Vass
New treatments may soon be available for patients with HIV which has become resistant to existing treatments.
The results are from completed phase III trials of a new category of anti-HIV drug called “fusion inhibitors.” The results show that twice as many patients using the first fusion inhibitor, T-20, in combination with antiretroviral drugs, achieved reductions in their viral load to below detectable levels, compared with patients taking antiretroviral drugs alone.
Significant improvements in immune cell (CD4) counts …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial